By Bibeka Shrestha

Law360, New York (July 19, 2011, 7:13 PM ET) -- The Arkansas Attorney General's Office said Tuesday that a state judge has nixed its claim that AstraZeneca Pharmaceuticals engaged in deceptive trade practices while marketing its schizophrenia and biopolar disorder drug Seroquel.

Circuit Judge Chris Piazza also scheduled a September 2012 trial for the state's other claim — that AstraZeneca Pharmaceuticals deceived the state into buying Seroquel for Medicaid patients by concealing health risks associated with the drug, according to Arkansas Attorney General Dustin McDaniel spokesman Aaron Sadler. The state alleges Seroquel can lead to stroke,...